% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • rakanobo rakanobo Dec 11, 2013 9:48 AM Flag

    NBS is a Must Buy over the next 12 months

    As of November, NBS was 10 patients shy of reaching full enrollment for its Phase 2 trial. Let me say it again, 10 PATIENTS SHY! The announcement of complete enrollment could come any day, or at any second!

    Once that happens, NBS will soar at least 10% because it means we are 6-9 months from final data. AMR-001 already has good data, and Baxter's data has been remarkable with its CD34+ product.

    There will be a lot of anticipation and NBS will get a pre-data run higher. The stock could easily be $11 by the time data is announced, and if positive, NBS will be a $25 stock.

    If for some reason data is bad, unlikely, NBS will be a $4 stock. Therefore, assess the upside/downside and you'll see that there's not much to lose, but a lot to gain.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.250.00(0.00%)Jun 5 3:59 PMEDT